IBEX Ltd (IBEX) officer receives 97,126 shares; 8,649 withheld for tax

Rhea-AI Filing Summary

IBEX Ltd’s Chief Sales/Marketing Officer, Julie K. Casteel, reported equity compensation activity in company common shares. On February 6, 2026, she acquired 97,126 restricted shares at $0 per share through a grant tied to a performance share award based on revenue and EBITDA targets.

On the same date, 8,649 shares were disposed of at $34.98 per share, representing shares withheld to cover taxes upon vesting. After these transactions, she directly held 116,794 common shares. One-third of the performance-based shares vested on February 6, 2026, with additional one-third tranches scheduled to vest on February 6, 2027 and February 6, 2028, subject to her continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Casteel Julie K

Role Chief Sales/Marketing Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	97,126	$0.00	--
Tax Withholding	Common Shares	8,649	$34.98	$303K

Holdings After Transaction: Common Shares — 125,443 shares (Direct)

Footnotes (1)

1. Reporting Person received this restricted stock award in connection with the vesting of an April 20, 2022 performance share award upon the attainment of certain Issuer Revenue and EBITDA targets for the trailing four (4) quarters. One-third of these shares vested on February 6, 2026. The remaining shares will vest one-third on February 6, 2027 and one-third on February 6, 2028. Vesting of performance share awards and shares issued in respect thereof is subject to the Reporting Person's continued service to the Company with Issuer through the applicable vesting date. Represents shares withheld for tax purposes upon vesting of restricted stock grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Casteel Julie K

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales/Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/06/2026		A		97,126	A	$0(1)	125,443	D
Common Shares	02/06/2026		F		8,649(2)	D	$34.98	116,794	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person received this restricted stock award in connection with the vesting of an April 20, 2022 performance share award upon the attainment of certain Issuer Revenue and EBITDA targets for the trailing four (4) quarters. One-third of these shares vested on February 6, 2026. The remaining shares will vest one-third on February 6, 2027 and one-third on February 6, 2028. Vesting of performance share awards and shares issued in respect thereof is subject to the Reporting Person's continued service to the Company with Issuer through the applicable vesting date.

2. Represents shares withheld for tax purposes upon vesting of restricted stock grant.

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IBEX (IBEX) report for Julie K. Casteel?

Julie K. Casteel, Chief Sales/Marketing Officer, acquired 97,126 restricted common shares on February 6, 2026 at $0 per share through an equity award. This reflects performance-based compensation rather than an open-market purchase.

Why were 8,649 IBEX (IBEX) shares disposed of in this Form 4?

The 8,649 common shares were disposed of at $34.98 per share to cover tax obligations arising from the vesting of a restricted stock grant. The filing specifies these shares were withheld for tax purposes rather than sold in the market.

How many IBEX (IBEX) shares does Julie K. Casteel own after the reported transactions?

Following the reported grant and tax-withholding disposition, Julie K. Casteel directly holds 116,794 IBEX common shares. This reflects her equity position after receiving 97,126 restricted shares and having 8,649 shares withheld to satisfy associated tax liabilities.

What performance conditions triggered Julie K. Casteel’s IBEX restricted stock award?

The restricted stock award was earned upon meeting revenue and EBITDA targets for the trailing four quarters under an April 20, 2022 performance share award. These financial metrics had to reach specified levels for the shares to vest.

What is the vesting schedule for Julie K. Casteel’s IBEX performance-based shares?

One-third of the performance-based shares vested on February 6, 2026. The remaining shares are scheduled to vest in two equal one-third installments on February 6, 2027 and February 6, 2028, contingent on her continued service with IBEX.

Are Julie K. Casteel’s IBEX shares subject to continued employment conditions?

Yes. The filing states that vesting of the performance share awards, and the shares issued upon vesting, is subject to her continued service with IBEX through each applicable vesting date in 2027 and 2028.